ASCL3

Across TCGA pan-cancer cohorts, ASCL3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ASCL3 data layer compared with 15 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ASCL3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ASCL3 expression acts as an unfavorable survival marker.

COAD and UCEC are the cancer types where ASCL3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	0.105	0.758	<.001	27	view →
UCEC	OS	Median	III,IV	0.050	0.588	.003	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ASCL3–COAD (DFS)

Open the COAD breakdown →